- Home
- HNST vs CAPR Comparison
HNST vs CAPR Comparison
Compare HNST & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNST
- CAPR
- Stock Information
- Founded
- HNST 2012
- CAPR 2005
- Country
- HNST United States
- CAPR United States
- Employees
- HNST N/A
- CAPR N/A
- Industry
- HNST Catalog/Specialty Distribution
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNST Consumer Discretionary
- CAPR Health Care
- Exchange
- HNST Nasdaq
- CAPR Nasdaq
- Market Cap
- HNST 500.5M
- CAPR 453.9M
- IPO Year
- HNST 2021
- CAPR N/A
- Fundamental
- Price
- HNST $4.86
- CAPR $11.66
- Analyst Decision
- HNST Buy
- CAPR Strong Buy
- Analyst Count
- HNST 4
- CAPR 8
- Target Price
- HNST $7.63
- CAPR $33.75
- AVG Volume (30 Days)
- HNST 2.5M
- CAPR 3.0M
- Earning Date
- HNST 08-07-2025
- CAPR 08-06-2025
- Dividend Yield
- HNST N/A
- CAPR N/A
- EPS Growth
- HNST N/A
- CAPR N/A
- EPS
- HNST N/A
- CAPR N/A
- Revenue
- HNST $389,373,000.00
- CAPR $17,363,588.00
- Revenue This Year
- HNST $7.07
- CAPR $258.96
- Revenue Next Year
- HNST $4.90
- CAPR $8.02
- P/E Ratio
- HNST N/A
- CAPR N/A
- Revenue Growth
- HNST 12.15
- CAPR N/A
- 52 Week Low
- HNST $2.89
- CAPR $3.52
- 52 Week High
- HNST $8.97
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- HNST 47.90
- CAPR 50.35
- Support Level
- HNST $4.72
- CAPR $9.65
- Resistance Level
- HNST $5.21
- CAPR $10.56
- Average True Range (ATR)
- HNST 0.19
- CAPR 1.21
- MACD
- HNST 0.01
- CAPR -0.02
- Stochastic Oscillator
- HNST 61.54
- CAPR 70.08
About HNST The Honest Company Inc.
The Honest Co Inc is a digitally-native consumer products company to makes purpose-driven consumer products designed for all people. It is an omnichannel brand, ensuring its products are available wherever its consumers shop through the company's Retail and Digital channels. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.